On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SARS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19). Due to the changes of immune function and cardiopulmonary function in overweight people, the infection and severity of these patients are higher than that of the general population during the epidemic period. More attention should be paid to personal protection and disease prevention. Vaccination with COVID-19 vaccine can effectively prevent COVID-19 infection, delay or prevent patients from developing into critical illness and reducing mortality. In order to evaluate the safety and efficacy of COVID-19 vaccine for overweight people, and to guide COVID-19 vaccination more scientifically, rationally and effectively, this study was carried out.
Due to the changes of immune function and cardiopulmonary function in overweight people, the infection and severity of these patients are higher than that of the general population during the epidemic period. More attention should be paid to personal protection and disease prevention. Vaccination of COVID-19 can effectively prevent COVID-19 virus infection and delay or prevent patients from developing into critical illness and reduce mortality. The safety and effectiveness of COVID-19 vaccine in this population were evaluated in order to play a scientific and theoretical supporting role in guiding COVID-19 vaccination more scientifically, reasonably and effectively. The samples of this study were collected and tested in the second affiliated Hospital of Chongqing Medical University. Patients with contraindications for vaccination will be excluded. The detected indexes included blood routine test, liver function, COVID-19 antibody titer, antibody duration and other indexes of healthy people (control group) and overweight people after vaccination ( 1, 3, 6 months after vaccination). The adverse reactions related to the vaccine were recorded.
Study Type
OBSERVATIONAL
Enrollment
450
The antibody titer and adverse reactions were observed.
China
Chongqing, China
RECRUITINGNumber of participants with adverse events after injection.
The vaccine-related adverse reactions (such as fever, dizziness, fatigue, myalgia, etc.) were recorded and its safety was evaluated.
Time frame: 1 month after vaccination
Number of participants with adverse events after injection.
The vaccine-related adverse reactions (such as fever, dizziness, fatigue, myalgia, etc.) were recorded and its safety was evaluated.
Time frame: 3 months after vaccination
Number of participants with adverse events after injection.
The vaccine-related adverse reactions (such as fever, dizziness, fatigue, myalgia, etc.) were recorded and its safety was evaluated.
Time frame: 6 months after vaccination
Titer and duration of COVID-19 antibody production after vaccination
The titer and duration of COVID-19 antibody were produced at 1 month
Time frame: 1 month after vaccination
Titer and duration of COVID-19 antibody production after vaccination
The titer and duration of COVID-19 antibody were produced at 3 months
Time frame: 3 months after vaccination
Titer and duration of COVID-19 antibody production after vaccination
The titer and duration of COVID-19 antibody were produced at 6 months
Time frame: 6 months after vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.